Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?

被引：0
|
作者：
Synnott, Naoise C.
Pierce, Aisling
Mullooly, Maeve
Caiazza, Francesco
McGowan, Patricia M.
O'Donovan, Norma
Crown, John
Duffy, Michael J.
机构：
[1] Univ Coll Dublin, Educ & Res Ctr, St Vincents Univ Hosp, Dublin 2, Ireland
[2] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland
[3] Dublin City Univ, Natl Inst Cellular Biotechnol, Mol Therapeut Canc Ireland, Dublin 9, Ireland
[4] Irish Clin Oncol Res Grp, Dublin, Ireland
[5] Mol Therapeut Canc Ireland, Dublin, Ireland
[6] Univ Coll Dublin, Clin Res Ctr, St Vincents Univ Hosp, Dublin 2, Ireland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1118
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
    Naoise C. Synnott
    David O’Connell
    John Crown
    Michael J. Duffy
    Breast Cancer Research and Treatment, 2020, 179 : 47 - 56
  • [22] COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
    Synnott, Naoise C.
    O'Connell, David
    Crown, John
    Duffy, Michael J.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) : 47 - 56
  • [23] Mutant p53 as a target for cancer treatment
    Duffy, Michael J.
    Synnott, Naoise C.
    Crown, John
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 258 - 265
  • [24] TARGETING MUTANT P53 FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER: A PRE-CLINICAL STUDY
    Lawless, A.
    O'Grady, S.
    Tang, M.
    Duffy, M. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (SUPPL 1) : S20 - S20
  • [25] ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 gain-of-function
    Bado, Igor
    Nikolos, Fotis
    Rajapaksa, Gayani
    Gustafsson, Jan-Ake
    Thomas, Christoforos
    CANCER RESEARCH, 2015, 75
  • [26] Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells
    Pileczki, Valentina
    Pop, Laura
    Braicu, Cornelia
    Budisan, Livia
    Morar, Gabriela Bolba
    Monroig-Bosque, Paloma del C.
    Sandulescu, Robert V.
    Berindan-Neagoe, Ioana
    ONCOTARGETS AND THERAPY, 2016, 9 : 6921 - 6933
  • [27] The expression of MELK, a growth regulator of triple-negative breast cancer, is regulated by p53
    Bollu, Lakshmi Reddy
    Brown, Powel H.
    Mazumdar, Abhijit
    Zhao, Dekuang
    Ma, Yanxia
    CANCER RESEARCH, 2017, 77
  • [28] Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
    Bae, Soo Youn
    Nam, Seok Jin
    Jung, Yongsik
    Lee, Sae Byul
    Park, Byung-Woo
    Lim, Woosung
    Jung, Sung Hoo
    Yang, Hsien Wen
    Jung, Seung Pil
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (02) : 437 - 444
  • [29] Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
    Soo Youn Bae
    Seok Jin Nam
    Yongsik Jung
    Sae Byul Lee
    Byung-Woo Park
    Woosung Lim
    Sung Hoo Jung
    Hsien Wen Yang
    Seung Pil Jung
    Breast Cancer Research and Treatment, 2018, 172 : 437 - 444
  • [30] Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers
    Morrison, Chevaun D.
    Chang, Jenny C.
    Keri, Ruth A.
    Schiemann, William P.
    CELL DEATH & DISEASE, 2017, 8 : e2899 - e2899
12345